Senti Biosciences (SNTI) said Monday that two of three acute myeloid leukemia patients treated with its Senti-202 investigational cell therapy for relapsed or refractory hematologic malignancies, or blood cancers, achieved complete remission in a phase 1 trial.

Both patients, who were treated at the lowest dose level, showed no measurable residual disease after treatment and maintained remission for over four and three months, respectively, the company said.

The therapy was well-tolerated, with no dose-limiting toxicities reported, Senti Biosciences said. Enrolment for a dose escalation phase is ongoing, with additional data expected in 2025, Senti added.

Shares of the company soared over 141% in recent premarket activity.